Germany’s federal parliament advanced a cost-saving bill that biopharma groups say could push drugmakers out, including a jump in mandatory manufacturer rebates. The legislation would raise the rebate on most branded prescription drugs from 7% to 15.5% and increase the discount on patented vaccines to 9%, alongside a vaccine price freeze from January 2027 through December 2030. The policy package also includes co-payment language adjusted for price and wage developments and references constraints that could limit manufacturers’ ability to offset inflation through pricing. Industry groups and Germany’s research-based pharmaceutical association have criticized the bill, while the U.S. trade representative has also initiated a Section 301 investigation into whether Germany’s pharma pricing policies discriminate against American commerce. The move matters for market access planning: it increases pressure for demonstrating value and navigating rebate-driven contracting dynamics, potentially reshaping launch decisions and portfolio prioritization across Europe’s largest healthcare market.